Violation Tracker Individual Record
Date:July 24, 2017
Primary Offense:False Claims Act
Secondary Offense:drug or medical equipment safety violation
Celgene Corp. agreed to pay $280 million to settle fraud allegations related to the promotion of two cancer treatment drugs for uses not approved by the Food and Drug Administration.
Level of Government:federal
Action Type:agency action
Agency:U.S. Attorney-Central District of California
Civil or Criminal Case:civil
HQ Country of Parent:USA
HQ State of Parent:New Jersey
Ownership Structure of Parent:publicly traded
Major Industry of Parent:pharmaceuticals
Specific Industry of Parent:pharmaceuticals
Source Notes:If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.